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Effectiveness of an Immediate Mitomycin C Instillation in Patients 
with Superficial Bladder Cancer Receiving Periodic Mitomycin C 
Instillation
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Department of Urology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea
Purpose: We analyzed the impact of immediate intravesical mitomycin C instillation 
after transurethral resection of the bladder (TURB) on tumor recurrence and pro-
gression in patients with periodic mitomycin C instillation.
Materials and Methods: Between June 2000 and June 2006, a retrospective study was 
performed in a total of 115 patients with primary bladder tumors receiving a 6-week 
course of mitomycin C instillation after TURB. The patients were assigned to two 
groups: 53 patients in the immediate mitomycin C (I-MMC) group were treated by im-
mediate instillation of mitomycin C after TURB and periodic instillation (6 times, 1 
time per week), and 62 patients in the MMC group received only periodic instillation. 
Tumor recurrence and progression were compared in the two groups.
Results: During the mean follow-up period of 46.5 months in the I-MMC group and 47.2 
months in the MMC group, early recurrence (within 1 year) occurred in 6 of 53 patients 
(11.3%) in the I-MMC group and in 18 of 62 patients (29.0%) in the MMC group (p＜0.02). 
Although a significantly lower early recurrence rate was observed in the I-MMC group, 
this difference was not significant for recurrence within 2 or 3 years or for total re-
currence. Progression was not significantly different between the two groups regarding 
the early and total period.
Conclusions: Our study confirmed the positive effect of a single, immediate mitomycin 
C instillation in patients with non-muscle-invasive bladder tumors who received peri-
odic mitomycin C instillation. This benefit was limited to early recurrence and was not 
maintained with long-term follow-up. This approach can be an alternative to periodic 
mitomycin C instillation without immediate instillation.
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INTRODUCTION
Transurethral resection of the bladder (TURB) followed by 
watchful waiting was usually performed for non-mus-
cle-invasive bladder cancer in the past, but immediate in-
travesical chemotherapy has recently frequently been 
used in clinics [1-4]. The European Association of Urology 
(EAU) guideline recommends performing an one-time, im-
mediate intravesical drug treatment after the surgery in 
all non-muscle-invasive bladder cancers [5], and intra-
vesical chemotherapy is known to be effective in preventing 
cancer recurrence by suppressing implantation of the post-
operative tumor cells wandering in the bladder after the 
surgery. On the other hand, in the case of non-muscle-in-
vasive bladder cancer patients in the intermediate risk 
group (TaG1 with multifocal or ＞3 cm diameter, TaG2, 
T1G1, T1G2) [6], periodic intravesical chemotherapy is 
performed with bacillus Calmette-Guerin (BCG) or mito-
mycin C after TURB, but it requires waiting 1 to 2 weeks 
to begin the treatment; thus, it is possible that recurrence Korean J Urol 2011;52:323-326
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TABLE 1. Patient characteristics
Immediate 
MMC group (%)
Non-immediate 
MMC group (%)
p-value
No. of patients  53 62
No. of tumors 53 62
Mean age (yr) 61.5±12.6 64.9±11.5 0.629
Clinical stage
　Ta 25/53 (47.2) 26/62 (41.9) 0.573
　T1 28/53 (52.8) 36/62 (58.1) 0.573
WHO grade
　Grade I 26/53 (49.1) 30/62 (48.4) 0.943
　Grade II 27/53 (50.9) 32/62 (51.6) 0.943
Mean follow up
  period (mo)
46.5±11.5 47.2±9.1 0.513
MMC: mitomycin C
TABLE 2. Recurrence and progression in each group according to
follow-up period
Immediate 
MMC group (%)
Non-immediate 
MMC group (%)
p-value
Recurrence
　Within 1 year   6/53 (11.3) 18/62 (29.0) 0.020
　Within 3 year 16/53 (30.2) 29/62 (46.8) 0.069
Progression
　Within 1 year 2/53 (3.8) 3/62 (4.8) 0.780
　Within 3 year   6/53 (11.3)   9/62 (14.5) 0.612
MMC: mitomycin C
or progression could be affected during this period [7,8]. 
Therefore, we performed immediate post-TURB mitomy-
cin C treatment in patients with non-muscle-invasive blad-
der cancer in the intermediate risk group who planned to 
undergo periodic intravesical mitomycin C instillation and 
investigated the effect of the treatment on the progression 
and recurrence of bladder cancer. 
MATERIALS AND METHODS
Between June 2000 and June 2006, a retrospective study 
was performed in patients with primary bladder tumors 
who underwent a 6-week course of mitomycin C instillation 
after TURB. Patients were limited to those with inter-
mediate-risk non-muscle-invasive bladder tumors. TURB 
was conducted by 2 surgeons regardless of the group of 
patients. Individuals with muscle-invasive or G3 tumors 
or in situ bladder carcinoma on the pathological examina-
tion, non-transitional-cell carcinoma, invasion to the pros-
tate or upper urinary tract, or a history of TURB or intra-
vesical chemotherapy were excluded. 
　Patients were divided into 2 groups. The immediate mi-
tomycin C (I-MMC) group consisted of 53 patients who re-
ceived a single dose of mitomycin C, 30 mg diluted in 30 ml 
of water, within 24 hours after TURB and received periodic 
mitomycin C instillation after 1 week (1-week interval for 
6 weeks). The non-immediate mitomycin C (MMC) group 
consisted of 62 patients who did not receive mitomycin C 
within 24 hours after TURB and only received periodic 
instillation. The instillation was retained for 1.5 to 2 hours 
by catheter and was then emptied out by self-voiding. 
Mitomycin C instillation was delayed for 1 or 2 weeks if 
complications such as severe irritative voiding symptoms, 
cystitis, allergic reactions, hematuria, fever, erythema, or 
skin rash appeared. 
　Patients were evaluated by urine cytology and cysto-
scopy at 3, 6, 9, 12, 18, and 24 months and then once yearly 
postoperatively. If hematuria developed, evaluation was 
done immediately. Tumor grade, stage, time of recurrence, 
grade of recurrent tumors, and progression of the two 
groups were compared by unpaired t-tests and chi-square 
tests. Values were considered statistically significant at p
＜0.05. 
RESULTS
Both groups (total of 115 patients), 53 patients in the I- 
MMC group and 62 patients in the MMC group, were com-
parable in terms of clinical and pathological characteristics 
(Table 1). There were no statistically significant differ-
ences between the 2 groups. 
　Recurrence timing was considered by using different cut-
off points when determining the possible impact of a single 
early instillation of mitomycin C on cell implantation as a 
mechanism of early recurrence. Early recurrence (within 
1 year) occurred in 6 of 53 patients (11.3%) in the I-MMC 
group and in 18 of 62 patients (29.0%) in the MMC group 
(p=0.020) (Table 2). Although the early recurrence rate was 
significantly lower in the I-MMC group, the difference be-
tween groups was not significant for recurrence within 3 
years or for total recurrence, which occurred in 16 of 53 pa-
tients (30.2%) in the I-MMC group versus 29 of 62 patients 
(46.8%) in the MMC group. Progression to a more advanced 
stage occurred in 2 of 53 patients (3.8%) in the I-MMC group 
and in 3 of 62 patients (4.8%) in the MMC group within 1 
year (p=0.780), and in 6 of 53 patients (11.3%) in the I-MMC 
group and in 9 of 62 patients (14.5%) in the MMC group 
within 3 years (p=0.612). Two of 53 patients (3.8%) in the 
I-MMC group and 2 of 62 patients (3.2%) in the MMC group 
had progression to muscle-invasive bladder cancer.
DISCUSSION
Post-TURB intravesical chemotherapy has been used for 
non-muscle-invasive bladder cancer for more than 40 years, 
and thiotepa, Adriamycin, Epodyl, epirubicin, and mito-
mycin C have been used for the periodic intravesical chemo-
therapy [6]. There have been several reports about the timing 
to begin the intravesical chemotherapy. Soloway and Mas-
ters reported in a study with murine bladder that post- 
TURB intravesical chemotherapy was effective even though 
it was performed after 24 hours [9], whereas Pan et al in-
sisted that intravesical chemotherapy was effective only Korean J Urol 2011;52:323-326
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when it was performed within 1 hour after the surgery [10]. 
According to an EORTC study that was conducted later us-
ing thiotepa, doxorubicin, and cisplatin, the disease-free 
interval was longer in the group in which the post-TURB 
intravesical chemotherapy was performed on the 4th to the 
14th day than in the group in which it was performed 0 to 
3 days after TURB or after the 14th day [11]. Furthermore, 
in a study conducted using mitomycin C and doxorubicin, 
it was reported that there was more benefit in the group 
in which the intravesical chemotherapy was performed be-
tween the 7th and 15th day than in the group in which the 
intravesical chemotherapy was performed on the day of the 
operation [12].
　Recently, many clinical studies have been performed re-
garding the effect of one-time immediate post-TURB mito-
mycin C instillation in the low-risk group of non-muscle-in-
vasive bladder cancer patients. Solsona et al reported in a 
randomized study with 131 subjects by short-term follow- 
up that the recurrence-free interval was longer and the re-
currence rate was lower in the group in which post-TURB 
immediate mitomycin C instillation was performed than 
in the group in which only TURB was performed for non- 
muscle-invasive bladder cancer [13]. Sylvester et al analy-
zed the studies on intravesical chemotherapy and reported 
that post-TURB immediate intravesical instillation of mi-
tomycin C, epirubicin, or pirarubicin showed a lower re-
currence rate than TURB only [14]. In our study, the effect 
of immediate MMC treatment was compared in the pa-
tients to which MMC treatment was performed periodi-
cally for intermediate-risk non-muscle-invasive bladder 
cancer, and the results showed that the recurrence rate 
within 1 year was significantly lower in the I-MMC group 
(11.3%) than in the MMC group (29.0%). Kaasinen et al in-
vestigated the factors for post-TURB recurrence in non- 
muscle-invasive bladder cancer patients and reported that 
the relative risk of recurrence was reduced to half when the 
first instillation of the periodic mitomycin C treatment was 
performed within 24 hours after TURB [15]. Our result was 
also similar to this report, and thus it can be assumed that 
the timing of mitomycin C administration affects the cata-
mnesis. On the other hand, the recurrence rate within 3 
years was lower in the I-MMC group (30.2%) than in the 
MMC group (46.8%) but not significantly so. Thus, it is hard 
to conclude that post-TURB immediate intravesical che-
motherapy is effective for the long-term suppression of 
recurrence. Additionally, tumor recurrence increased about 
3 times between within 1 year (11.3%) and within 3 years 
(30.2%) in I-MMC group, whereas it increased about 1.5 
times between within 1 year (29.0%) and within 3 years 
(46.8%) in the MMC group. Thus, patients who receive im-
mediate MMC instillation may need more frequent fol-
low-up than patients who do not receive immediate MMC 
instillation. Additional studies are required in this regard 
through the study of a greater number of cases.
　In a study with 43 low-risk non-muscle-invasive bladder 
cancer patients, Barghi et al reported that there was no sig-
nificant difference in tumor progression between the group 
in which immediate post-TURB intravesical chemotherapy 
was performed and the group in which only TURB was per-
formed [6]. In another study with 63 low-risk non-muscle- 
invasive bladder cancer patients, El-Ghobashy et al re-
ported that immediate post-TURB intravesical chemo-
therapy did not show any effect on tumor progression [16]. 
In our study also, tumor progression in the I-MMC group 
was 3.7% within 1 year and 11.3% within 3 years, and that 
in the MMC group was 4.8% within 1 year and 14.5% within 
3 years, showing no significant difference.
　The effect of immediate post-TURB intravesical chemo-
therapy may be chemoresection of the residual tumor that 
can be implanted on the resection site or the tumor cells 
wandering inside the bladder [6]. This article is the first 
study that investigated the effect of immediate post-TURB 
mitomycin C instillation in an intermediate-risk group of 
non-muscle-invasive bladder cancer patients in whom pe-
riodic mitomycin C treatment was performed. Our results 
suggest that chemoresection may be effective not only in 
the low-risk group but also in the intermediate-risk group 
of non-muscle-invasive bladder cancer patients. 
　There is a possibility that the number of total intra-
vesical mitomycin C instillations may affect the results, be-
cause the I-MMC group had 7 instillations, whereas the 
MMC group had 6 instillations. Additional studies might 
be required in this regard.
CONCLUSIONS
In the intermediate-risk group of non-muscle-invasive 
bladder cancer patients in whom periodic post-TURB mito-
mycin C instillation is performed, one-time immediate 
post-TURB mitomycin C instillation does not affect the 
long-term recurrence or progression of bladder cancer but 
is effective in the suppression of early recurrence.
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